inositol polyphosphate-4-phosphatase type II BGenealiases: []
Q-omics provides the consensus-scored INPP4B profile across patient tissues and cancer cell-line models. INPP4B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, INPP4B is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, INPP4B protein abundance shows 40,105 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where INPP4B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INPP4B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INPP4B survival associations across molecular data types. INPP4B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INPP4B RNA expression–survival associations across cancer types. High INPP4B expression shows unfavorable associations in MESO, LUSC and KIRP, but favorable associations in KIRC, BRCA and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for INPP4B RNA expression.
This table summarizes INPP4B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for INPP4B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INPP4B shows lower tumor expression in UCEC and THCA and higher tumor expression in BLCA, HNSC, LUAD and CHOL. The BLCA box plot shows higher INPP4B RNA expression in tumor versus normal tissue (log2 FC = +0.936, t-test p = .004).
This table shows molecular features associated with INPP4B in patient tissues and cancer cell lines. In patient samples, INPP4B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, INPP4B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BONE.
